David Micklem

The University of Texas Health Science Center at San Antonio — United States

Immunology and Microbiology · Life Sciences

23h-index3.5kcitations120works3.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Phagocytosis and Immune Regulation(67), Pancreatic and Hepatic Oncology Research(36), Nanoplatforms for cancer theranostics(17), Chronic Lymphocytic Leukemia Research(17), Cancer Research and Treatments(14)

Publications120 total

Structural Analysis of Tilvestamab in Complex with AXL
ACS Omega·2025Open Access
Paratope mapping of tilvestamab, an anti-AXL function-blocking antibody, using high-throughput bacterial expression of secreted scFv-osmY fusion proteins
Bioscience Reports·2025Open Access
A phase 1b, multicentre, dose escalation, safety and pharmacokinetics study of tilvestamab (BGB149) in relapsed, platinum-resistant, high-grade serous ovarian cancer (PROC) patients
British Journal of Cancer·2025· 2 citedOpen Access
Abstract LB401: Bemcentinib and pembrolizumab may overcome exhaustive immune phenotypes in patients with treatment refractory lung adenocarcinoma and reveals a potential STAT3 bypass mechanism
Cancer Research·2025
Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b/2a trial
Nature Communications·2025· 13 citedOpen Access
AXL-TBK1 driven AKT3 activation promotes metastasis
Science Signaling·2024· 5 citedOpen Access
Paratope mapping of tilvestamab, an anti-AXL function blocking antibody, using high-throughput bacterial expression of secreted scFv-ompY fusion proteins
2024Open Access
Structural analysis of tilvestamab in complex with AXL
2024Open Access
AXL expression reflects tumor-immune cell dynamics impacting outcome in non-small cell lung cancer patients treated with immune checkpoint inhibitor monotherapy
Frontiers in Immunology·2024· 13 citedOpen Access
In vivo turnover and biodistribution of soluble AXL: implications for biomarker development
Scientific Reports·2024· 3 citedOpen Access
AML Treatment By the AXL Inhibitor Bemcentinib in Combination with Cytarabine Shows Clinical Efficacy Related to TNFα and Cytotoxic Immune Cells: A Single-Cell Translational Study from the BGBC003 Trial
Blood·2023· 2 cited
PR070/#391  Phase I trial of tilvestamab, a function-blocking antibody inhibiting AXL, in platinum-resistant/refractory high grade serous ovarian cancer (PROC)
2023· 1 citedOpen Access
598 Bemcentinib + pembrolizumab show promising efficacy in metastatic NSCLC harbouring mutations associated with poor prognosis: exploratory sub-analysis from the BGBC008 trial (NCT03184571)
Regular and Young Investigator Award Abstracts·2023Open Access
1440P Final top-line results of the BGBC008 phase II, multicenter study of bemcentinib and pembrolizumab (bem+pembro) in second-line (2L) advanced non-squamous (NS) non-small cell lung cancer (NSCLC) (NCT03184571)
Annals of Oncology·2023· 4 citedOpen Access
Contents
Lung Cancer·2023Open Access
Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer
Lung Cancer·2023· 36 citedOpen Access
Abstract 3245: AXL as a therapeutic target in STK11 mutant NSCLC
Cancer Research·2023
Supplementary Figures S1-S6 from Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis
2023Open Access
Data from Nitroreductase, a Near-Infrared Reporter Platform for <i>In Vivo</i> Time-Domain Optical Imaging of Metastatic Cancer
2023Open Access
Supplementary Tables S1-S2 from Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis
2023Open Access
page 1 of 6Next →

Frequent Co-authors

James B. Lorens(34), Gro Gausdal(11), Bjørn Tore Gjertsen(10), Rolf A. Brekken(9), Monica Hellesøy(7), Austin Rayford(7), Hallvard Haugen(6), Emmet McCormack(6), John D. Minna(6), Hani Gabra(6), Murray Yule(6), Sonja Loges(6), Michael Heuser(6), Isabel Ben‐Batalla(6), Walter Fiedler(6), Crina Tiron(5), Lars A. Akslen(5), Katarzyna Wnuk-Lipińska(5), David E. Gerber(5), Magnus Blø(5)